Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVJF) Preferred Shares (2016 - 2018)

Teva Pharmaceutical Industries (TEVJF) has disclosed Preferred Shares for 3 consecutive years, with $3.8 billion as the latest value for Q3 2018.

  • For the quarter ending Q3 2018, Preferred Shares changed N/A year-over-year to $3.8 billion, compared with a TTM value of $3.8 billion through Sep 2018, changed N/A, and an annual FY2016 reading of $3.6 billion, up 10.0% over the prior year.
  • Preferred Shares was $3.8 billion for Q3 2018 at Teva Pharmaceutical Industries, up from $3.8 billion in the prior quarter.
  • Across five years, Preferred Shares topped out at $3.8 billion in Q3 2018 and bottomed at $3.3 billion in Q4 2015.
  • Average Preferred Shares over 3 years is $3.6 billion, with a median of $3.7 billion recorded in 2018.
  • Peak annual rise in Preferred Shares hit 10.0% in 2016, while the deepest fall reached 10.0% in 2016.
  • Year by year, Preferred Shares stood at $3.3 billion in 2015, then increased by 10.0% to $3.6 billion in 2016, then rose by 5.66% to $3.8 billion in 2018.
  • Business Quant data shows Preferred Shares for TEVJF at $3.8 billion in Q3 2018, $3.8 billion in Q2 2018, and $3.7 billion in Q1 2018.